Anti-Citrulline Antibodies in the Diagnosis and Prognosis of Rheumatoid Arthritis: Evolving Concepts

REFERENCES

• Vossenaar E R, van Venrooij W J. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 2004; 6: 107–111
   PubMedGoogle Scholar
• Yamada R, Suzuki A, Chang X, Yamamoto K. Citrullinated proteins in rheumatoid arthritis. Front Biosci 2005; 10: 54–64
   PubMed Web of Science ®Google Scholar
• Curis E, Nicolis I, Moinard C, Osowska S, Zerrouk N, Benazeth S, Cynober L. Almost all about citrulline in mammals. Amino Acids 2005; 29: 177–205
   PubMed Web of Science ®Google Scholar
• Nijenhuis S, Zendman A J, Vossenaar E R, Pruijn G J, van Venrooij W J. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of a RA-specific marker. Clin Chim Acta 2004; 350: 17–34
   PubMed Web of Science ®Google Scholar
• Watanabe K, Senshu T. Isolation and characterization of cDNA clones encoding rat skeletal muscle peptidylarginine deiminase. J Biol Chem 1989; 264: 15255–15260
   PubMedGoogle Scholar
• Vossenaar E R, Zendman A J, van Venrooij W J, Pruijn G J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003; 25: 1106–1118
   PubMed Web of Science ®Google Scholar
• Vossenaar E R, Radstake T R, van der Heijden A, van Mansum M A, Dieteren C, de Rooij D J, Barrera P, Zendman A J, van Venrooij W J. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004; 63: 373–381
   PubMed Web of Science ®Google Scholar
• Rogers G, Winter B, McLaughlan C, Powell B, Nesci T. Peptidylarginine deiminase of the hair follicle: characterization, localization, and function in keratinizing tissues. J Invest Dermatol 1997; 108: 700–707
   PubMed Web of Science ®Google Scholar
• Moscarello M A, Wood D D, Ackerley C, Boulias C. Myelin in multiple sclerosis is developmentally immature. J Clin Invest 1994; 94: 146–154
   PubMed Web of Science ®Google Scholar
• Nakashima K, Hagiwara T, Yamada M. Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J Biol Chem 2002; 277: 49562–49568
   PubMed Web of Science ®Google Scholar
• Nakashima K, Hagiwara T, Ishigami A, Nagata S, Asaga H, Kuramoto M, Senshu T, Yamada M. Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha,25-dihydroxyvitamin D(3). J Biol Chem 1999; 274: 27786–27792
   PubMed Web of Science ®Google Scholar
• Yamakoshi A, Ono H, Nishijyo T, Shiraiwa M, Takahara H. Cloning of cDNA encoding a novel isoform (type IV) of peptidylarginine deiminase from rat epidermis. Biochim Biophys Acta 1998; 1386: 227–232
   PubMedGoogle Scholar
• Ishigami A, Kuramoto M, Yamada M, Watanabe K, Senshu T. Molecular cloning of two novel types of peptidylarginine deiminase cDNAs from retinoic acid-treated culture of a newborn rat keratinocyte cell line. FEBS Lett 1998; 433: 113–118
   PubMedGoogle Scholar
• Hingorani K, Szebeni A, Olson M O. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000; 275: 24451–24457
   PubMed Web of Science ®Google Scholar
• Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene 2002; 21: 6170–6174
   PubMed Web of Science ®Google Scholar
• Takemura M, Ohoka F, Perpelescu M, Ogawa M, Matsushita H, Takaba T, Akiyama T, Umekawa H, Furuichi Y, Cook P R, Yoshida S. Phosphorylation-dependent migration of retinoblastoma protein into the nucleolus triggered by binding to nucleophosmin/B23. Exp Cell Res 2002; 276: 233–241
   PubMedGoogle Scholar
• Chavanas S, Mechin M C, Takahara H, Kawada A, Nachat R, Serre G, Simon M. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6. Gene 2004; 330: 19–27
   PubMed Web of Science ®Google Scholar
• Tarcsa E, Marekov L N, Mei G, Melino G, Lee S C, Steinert P M. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 1996; 271: 30709–30716
   PubMed Web of Science ®Google Scholar
• van Boekel M A, Vossenaar E R, van den Hoogen F H, van Venrooij W J. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 87–93
   PubMedGoogle Scholar
• Hill J A, Southwood S, Sette A, Jevnikar A M, Bell D A, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171: 538–541
   PubMed Web of Science ®Google Scholar
• van Gaalen F, Ioan-Facsinay A, Huizinga T W, Toes R E. The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. J Immunol 2005; 175: 5575–5580
   PubMed Web of Science ®Google Scholar
• Senshu T, Kan S, Ogawa H, Manabe M, Asaga H. Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem Biophys Res Commun 1996; 225: 712–719
   PubMedGoogle Scholar
• Chang X, Han J. Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 2006; 45: 183–196
   PubMed Web of Science ®Google Scholar
• Chang X, Yamada R, Sawada T, Suzuki A, Kochi O, Yamamoto K. Citrullination of fibronectin in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1374–1382
   PubMedGoogle Scholar
• Weyand C M, Goronzy J J. Pathomechanisms in rheumatoid arthritis—time for a string theory?. J Clin Invest 2006; 116: 869–871
   PubMed Web of Science ®Google Scholar
• Nienhuis R L, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 1964; 23: 302–305
   PubMed Web of Science ®Google Scholar
• Hoet R M, Boerbooms A M, Arends M, Ruiter D J, van Venrooij W J. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis 1991; 50: 611–618
   PubMed Web of Science ®Google Scholar
• Young B J, Mallya R K, Leslie R D, Clark C J, Hamblin T J. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979; 2: 97–99
   PubMed Web of Science ®Google Scholar
• Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux J J, Serre G. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95: 2672–2679
   PubMed Web of Science ®Google Scholar
• Despres N, Boire G, Lopez-Longo F J, Menard H A. The Sa system: a novel antigen–antibody system specific for rheumatoid arthritis. J Rheumatol 1994; 21: 1027–1033
   PubMed Web of Science ®Google Scholar
• Hayem G, Chazerain P, Combe B, Elias A, Haim T, Nicaise P, Benali K, Eliaou J F, Kahn M F, Sany J, Meyer O. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999; 26: 7–13
   PubMed Web of Science ®Google Scholar
• Hueber W, Hassfeld W, Smolen J S, Steiner G. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 155–159
   PubMedGoogle Scholar
• Schellekens G A, de Jong B A, van den Hoogen F H, van de Putte L B, van Venrooij W J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101: 273–281
   PubMed Web of Science ®Google Scholar
• Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Noqueira L, Vincent C, Senshu T, Serre G. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001; 166: 4177–4184
   PubMed Web of Science ®Google Scholar
• Vossenaar E R, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, van Venrooij W J, Menard H A. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6: R142–R150
   PubMed Web of Science ®Google Scholar
• Nakashima K, Hagiwara T, Yamada M. Nuclear localization of peptidylarginine deiminase v and histone deimination in granulocytes. J Biol Chem 2002; 277: 49562–49568
   PubMed Web of Science ®Google Scholar
• Chapuy-Regaud S, Sebbag M, Nachat R, Baeten D, Foulquier V, Simon M, Senshue T, Yamada M, Takahara H, De Keyser F, Serre G. Peptidylarginine deiminase isoforms expressed in the synovial membrane of rheumatoid arthritis patients. Arthritis Res Ther 2003; 5(Suppl 1)5, (abstract)
   PubMedGoogle Scholar
• Linn-Rasker S P, van der Helm-van Mil A H, van Gaalen F A, Kloppenburg M, de Vries R R, le Cessie S, Breedveld F C, Toes R E, Huizinga T W. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry shared epitope alleles HLA-DRB1. Ann Rheum Dis 2006; 65: 366–371
   PubMed Web of Science ®Google Scholar
• Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Ronnelid J, Harris H E, Ulfgren A K, Rantapaa-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38–46
   PubMed Web of Science ®Google Scholar
• Rubin B, Sonderstrup G. Citrullination of self-proteins and autoimmunity. Scand J Immunol 2004; 60: 112–120
   PubMedGoogle Scholar
• van Gaalen F A, van Aken J, Huizinga T W, Schreuder G M, Breedveld F C, Zanelli E, van Venrooij W J, Verweij C L, Toes R E, de Vries R R. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) affects severity of rheumatoid arthritis. Arthritis Rheum 2004; 50: 2113–2121
   PubMed Web of Science ®Google Scholar
• Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, van Venrooij W J, Klareskog L, Dahlqvist S R. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004; 6: R303–R308
   PubMed Web of Science ®Google Scholar
• Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395–402
   PubMed Web of Science ®Google Scholar
• Barton A, Bowes J, Eyre S, Spreckley K, Hinks A, John S, Worthington J. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum 2004; 50: 1117–1121
   PubMed Web of Science ®Google Scholar
• Caponi L, Petit-Teixeira E, Sebbag M, Bongiorni F, Moscato S, Pratesi F, Pierlot C, Osorio J, Chapuy-Regaud S, Guerrin M, Cornelis F, Serre G. Migliorini P; ECRAF. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann Rheum Dis 2005; 64: 587–593
   PubMed Web of Science ®Google Scholar
• Mimori T. Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med 2005; 44: 1122–1126
   PubMed Web of Science ®Google Scholar
• Schellekens G A, Visser H, de Jong B A, van den Hoogen F H, Hazes J M, Breedveld F C, van Venrooij W J. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155–163
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen J S, Steiner G, Rosen A, Zhang C, Menard H A, Zhou Z J, Palosuo T, Van Venrooij W J, Wilder R L, Klippel J H, Schumacher H R, Jr., El-Gabalawy H S. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2: 236–243
   PubMedGoogle Scholar
• Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089–1093
   PubMed Web of Science ®Google Scholar
• Bas S, Perneger T V, Seitz M, Tiercy J M, Roux-Lombard P, Guerne P A. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002; 41: 809–814
   PubMed Web of Science ®Google Scholar
• Rantapaa-Dahlqvist S, de Jong B A, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij W J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741–2749
   PubMed Web of Science ®Google Scholar
• Vossenaar E R, van Venrooij W J. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004; 4: 239–262
   Google Scholar
• Jansen A L, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt R J, de Koning M H, Dijkmans B A. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002; 29: 2074–2076
   PubMed Web of Science ®Google Scholar
• Kroot E J, de Jong B A, van Leeuwen M A, Swinkels H, van den Hoogen F H, van't Hof M, van de Putte L B, van Rijswijk M H, van Venrooij W J, van Riel P L. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831–1835
   PubMed Web of Science ®Google Scholar
• Union A, Meheus L, Humbel R L, Conrad K, Steiner G, Moereels H, Pottel H, Serre G, De Keyser F. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 2002; 46: 1185–1195
   PubMedGoogle Scholar
• De Rycke L, Peene I, Hoffman I E, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Boullart L, Serre G, Veys E M, De Keyser F. Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis 2004; 63: 1587–1593
   PubMed Web of Science ®Google Scholar
• Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120–126
   PubMed Web of Science ®Google Scholar
• Vincent C, Nogueira L, Clavel C, Sebbag M, Serre G. Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 2005; 38: 17–24
   PubMed Web of Science ®Google Scholar
• Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65: 845–851
   PubMed Web of Science ®Google Scholar
• Palazzi C, Padula A, Hepatitis C. virus and arthritis. Rheum Dis Clin North Am 2003; 29: 111–122
   PubMedGoogle Scholar
• Wener M H, Hutchinson K, Morishima C, Gretch D R. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 2004; 50: 2305–2308
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Alessandri C, Labbadia G, Iannuccelli C, Carlucci F, Riccieri V, Paoletti V, Valesini G. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004; 6: R137–R141
   PubMed Web of Science ®Google Scholar
• Mediwake R, Isenberg D A, Schellekens G A, van Venrooij W J. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001; 60: 67–68
   PubMed Web of Science ®Google Scholar
• van Noord C, Hooijkaas H, Dufour-van den Goorbergh B C, van Hagen P M, van Daele P L, van de Merwe J P. Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjögren's syndrome. Ann Rheum Dis 2005; 64: 160–162
   PubMed Web of Science ®Google Scholar
• Gottenberg J E, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, Labarre C, Meyer O, Sibilia J, Mariette X. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 2005; 64: 114–117
   PubMed Web of Science ®Google Scholar
• Alenius G M, Berglin E, Rantapää Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006; 65: 398–400
   PubMed Web of Science ®Google Scholar
• Avcin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, Porenta-Besic V, Cecchini G, Borghi M O, Meroni P L. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002; 61: 608–611
   PubMed Web of Science ®Google Scholar
• van Rossum M, van Soebergen R, de Kort S, ten Cate R, Zwinderman A H, de Jong B, Dijkmans B, van Venrooij W J. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003; 30: 825–828
   PubMed Web of Science ®Google Scholar
• Low J M, Chauhan A K, Kietz D A, Daud U, Pepmueller P H, Moore T L. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004; 31: 1829–1833
   PubMed Web of Science ®Google Scholar
• Ferucci E D, Majka D S, Parrish L A, Moroldo M B, Ryan M, Passo M, Thompson S D, Deane K D, Rewers M, Arend W P, Glass D N, Norris J M, Holers V M. Antibodies against cyclic citrullinated peptide are associated with HLA-DR 4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2005; 52: 239–246
   PubMedGoogle Scholar
• Kwok J S, Hui K H, Lee T L, Wong W, Lau Y L, Wong R W, Kim D L, Jones B M. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005; 34: 359–366
   PubMed Web of Science ®Google Scholar
• Makrygiannakis D, af Klint E, Lundberg I E, Loftberg R, Ulfgren A K, Klareskog L, Catrina A I. Citrullination is an inflammation dependent process. Ann Rheum Dis 2006; 65: 1219–1222
   PubMed Web of Science ®Google Scholar
• O'Dell J R. Treating rheumatoid arthritis early: a window of opportunity?. Arthritis Rheum 2002; 46: 283–285
   PubMed Web of Science ®Google Scholar
• Landewe R B, Boers M, Verhoeven A C, Westhovens R, van de Laar M A, Markusse H M, van Denderen J C, Westedt M L, Peeters A J, Dijkmans B A, Jacobs P, Boonen A, van der Heijde D M, van der Linden S. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347–356
   PubMed Web of Science ®Google Scholar
• Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, van Venrooij W J, Klareskog L, Dahlqvist S R. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004; 6: R303–R308
   PubMed Web of Science ®Google Scholar
• Nielen M M, van Schaardenburg D, Reesink H W, van de Stadt R J, van der Horst-Bruinsma I E, de Koning M H, Habibuw M R, Vandenbroucke J P, Dijkmans B A. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380–386
   PubMed Web of Science ®Google Scholar
• Jansen A L, van der Horst-Bruinsma I E, van Schaardenburg D, van de Stadt R J, de Koning M H, Dijkmans B A. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002; 29: 2074–2076
   PubMed Web of Science ®Google Scholar
• van Gaalen F A, Linn-Rasker S, van Venrooij W J, de Jong B A, Breedveld F C, Verweij C L, Toes R E, Huizinga T W. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 2004; 50: 709–715
   PubMed Web of Science ®Google Scholar
• Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D, Gervasi G, Menard J F, Gayet A, Fardellone P, Daragon A, Jolivet M, le Loet X, Tron F. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 2004; 135: 173–180
   PubMedGoogle Scholar
• Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 427–430
   PubMed Web of Science ®Google Scholar
• Visser H, le Cessie S, Vos K, Breedveld F C, Hazes J M. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357–365
   PubMed Web of Science ®Google Scholar
• Jansen L M, van Schaardenburg D, van der Horst-Bruinsma I E, van der Stadt R J, de Koning M H, Dijkmans B A. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003; 30: 1691–1695
   PubMed Web of Science ®Google Scholar
• Forslind K, Ahlmen M, Eberhardt K, Hafstrom I. Svensson B; BARFOT Study Group. Prediction of radiological outcome in early RA in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63: 1090–1095
   PubMed Web of Science ®Google Scholar
• Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during three years in early rheumatoid arthritis (the TIRA project). Ann Rheum Dis 2004; 63: 1085–1089
   PubMed Web of Science ®Google Scholar
• van Boekel M A, Vossenaar E R, van den Hoogen F H, van Venrooij W J. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 87–93
   PubMedGoogle Scholar
• Marcelletti J F, Nakamura R M. Assessment of serological markers associated with rheumatoid arthritis: diagnostic autoantibodies and conventional disease activity markers. Clin Appl Immunol Rev 2003; 4: 109–123
   Google Scholar
• Steiner G, Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 2002; 4(Suppl 2)S1–S5
   PubMedGoogle Scholar
• Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004; 6: R264–R272
   PubMed Web of Science ®Google Scholar
• Chen H A, Lin K C, Chen C H, Liao H T, Wang H P, Chang H N, Tsai C Y, Chou C T. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 35–39
   PubMed Web of Science ®Google Scholar